Daniel C. Adelman

4.5k total citations · 1 hit paper
78 papers, 3.1k citations indexed

About

Daniel C. Adelman is a scholar working on Immunology and Allergy, Immunology and Surgery. According to data from OpenAlex, Daniel C. Adelman has authored 78 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology and Allergy, 18 papers in Immunology and 15 papers in Surgery. Recurrent topics in Daniel C. Adelman's work include Food Allergy and Anaphylaxis Research (21 papers), Allergic Rhinitis and Sensitization (12 papers) and Celiac Disease Research and Management (12 papers). Daniel C. Adelman is often cited by papers focused on Food Allergy and Anaphylaxis Research (21 papers), Allergic Rhinitis and Sensitization (12 papers) and Celiac Disease Research and Management (12 papers). Daniel C. Adelman collaborates with scholars based in United States, Germany and United Kingdom. Daniel C. Adelman's co-authors include Eric Holmgren, Kim Margolin, Michael S. Gordon, George W. Sledge, Moshe Talpaz, S. Shak, Robert S. Benjamin, Alkis Togias, Andrew Saxon and Emmanuel Saltiel and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Daniel C. Adelman

74 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

2001 744 citations Daniel C. Adelman et al. profile →

Peers

Countries citing papers authored by Daniel C. Adelman

Since Specialization

Citations

This map shows the geographic impact of Daniel C. Adelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Adelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Adelman more than expected).

Fields of papers citing papers by Daniel C. Adelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Adelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Adelman. The network helps show where Daniel C. Adelman may publish in the future.

Co-authorship network of co-authors of Daniel C. Adelman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel C. Adelman. A scholar is included among the top collaborators of Daniel C. Adelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel C. Adelman. Daniel C. Adelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Initial results from BEACON, a phase 1b/2a dose escalation study of the anti-c-Kit briquilimab antibody in adults with chronic spontaneous urticaria (CSU) 2025 ·Journal of Allergy and Clinical Immunology ·Thomas B. Casale, Edwin W. Tucker, Jinwei Yuan, Daniel C. Adelman, David N. Ku, Annette Marcantonio, (unknown), (unknown), Wendy W. Pang, Marcus Maurer, Martin Metz	1
2	Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial 2024 ·Clinical and Translational Allergy ·Caroline Nilsson, Andrea Vereda, Magnus P. Borres, Mats Andersson, (unknown), (unknown), (unknown), Reyna J. Simon, Robert Ryan, Montserrat Fernández‐Rivas, Daniel C. Adelman, Brian P. Vickery	1
3	Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy 2022 ·Journal of Allergy and Clinical Immunology ·R. Sharon Chinthrajah, Stacie M. Jones, Edwin Kim, Scott H. Sicherer, Wayne G. Shreffler, Bruce J. Lanser, (unknown), Denise C. Babineau, Daniel C. Adelman, Ahmar Iqbal, Susan L. Limb, Amanda K. Rudman Spergel, Alkis Togias, Robert A. Wood	45
4	Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials 2021 ·Journal of Allergy and Clinical Immunology ·Kari Brown, James R. Baker, Andrea Vereda, Kirsten Beyer, A. Wesley Burks, George Du Toit, Jonathan O’B Hourihane, Stacie M. Jones, (unknown), Adrian Dana, Wayne G. Shreffler, Brian P. Vickery, Thomas B. Casale, (unknown), Daniel C. Adelman	15
5	At-home Dosing Adherence During Characterized Oral Desensitization Immunotherapy (CODIT) for Peanut Allergy 2017 ·Journal of Allergy and Clinical Immunology ·Stacie M. Jones, Brian P. Vickery, J. Andrew Bird, Jonathan M. Spergel, Rima Rachid, Amal Assa’ad, Julie Wang, Stephanie A. Leonard, Susan Laubach, Edwin Kim, Benjamin P. Davis, Michael J. Welch, Jennifer Heimall, Antonella Cianferoni, Andrew J. MacGinnitie, Elena Crestani, Amr Radwan, Andrea Vereda, Daniel C. Adelman, A. Wesley Burks	1
6	A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease 2017 ·Cellular and Molecular Gastroenterology and Hepatology ·Mitchell Garber, (unknown), Joel S. Parker, Wendell Jones, Katri Kaukinen, Kaija Laurila, Marja‐Leena Lähdeaho, Purvesh Khatri, Chaitan Khosla, Daniel C. Adelman, Markku Mäki	8
7	Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials 2011 ·Digestive Diseases and Sciences ·Matthew Siegel, Mitchell Garber, Andrew Spencer, (unknown), Pawan Kumar, R Williams, Kenji Kozuka, Revati Shreeniwas, Vijaya S. Pratha, Daniel C. Adelman	78
8	Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer 2011 ·Journal of Thoracic Oncology ·Lee M. Krug, Jeffrey Crawford, David S. Ettinger, Geoffrey I. Shapiro, David R. Spigel, Tony Reiman, Jennifer S. Temel, Glenn Michelson, Donald Y. Young, Ute Hoch, Daniel C. Adelman	18
9	A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors 2007 ·Investigational New Drugs ·Elisabeth I. Heath, Keith C. Bible, Robert E. Martell, Daniel C. Adelman, Patricia LoRusso	89
10	Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis 2004 ·Annals of Allergy Asthma & Immunology ·Jonathan Corren, David Díaz-Sánchez, Andrew Saxon, Yamo Deniz, James D. Reimann, (unknown), (unknown), Daniel C. Adelman	24
11	Incidence and characteristics of ruptured plaque in Femoro-Popliteal arteries 2003 ·Journal of the American College of Cardiology ·Yoichiro Hongo, (unknown), Krishnankutty Sudhir, Daniel C. Adelman, Yasuhiro Honda, Paul G. Yock, Peter J. Fitzgerald	1
12	Photodynamic therapy: Applications in atherosclerotic vascular disease with motexafin lutetium 2002 ·Catheterization and Cardiovascular Interventions ·Tony M. Chou, Kathryn W. Woodburn, Wai‐Fung Cheong, Steven Lacy, Krishnankutty Sudhir, Daniel C. Adelman, Dennis Wahr	32
13	Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects 1999 ·American Journal of Respiratory and Critical Care Medicine ·JOHN V. FAHY, Donald W. Cockcroft, Louis‐Philippe Boulet, Hofer Wong, Francine Deschesnes, (unknown), Jane Ruppel, John Q. Su, Daniel C. Adelman	121
14	CD45 isoforms on human CD4+ T-cell subsets 1996 ·Journal of Allergy and Clinical Immunology ·(unknown), Hans Yssel, Carol Soderberg, Lawrence Steinman, Daniel C. Adelman, Gary Peltz, Riitta Lahesmaa	10
15	Core content outline for clinical and laboratory immunology 1994 ·Journal of Allergy and Clinical Immunology ·William T. Shearer, Daniel C. Adelman, David P. Huston, Renata J.M. Engler, (unknown), Dennis K. Ledford, (unknown), (unknown)	3
16	Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide 1993 ·Journal of Allergy and Clinical Immunology ·Avi Hassner, M. Lau, Edward J. Goetzl, Daniel C. Adelman	18
17	Biologic Response Modifiers in Primary Immunodeficiency Disorders 1991 ·Annals of Internal Medicine ·Avi Hassner, Daniel C. Adelman	6
18	13-Cis retinoic acid enhances in vivo B-lymphocyte differentiation in patients with common variable immunodeficiency 1991 ·Journal of Allergy and Clinical Immunology ·Daniel C. Adelman, (unknown), William G. Cumberland, Neil Sidell, Andrew Saxon	14
19	Neuroimmunology 1990 ·Advances in immunology ·E J Goetzl, Daniel C. Adelman, Sunil P. Sreedharan	51
20	Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency. 1988 ·The Journal of Experimental Medicine ·Elliott H. Sherr, Daniel C. Adelman, Andrew Saxon, (unknown), Randolph Wall, Neil Sidell	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact